Session

IBD (Posters)

USTEKINUMAB FOR ULCERATIVE COLITIS A REAL-WORLD EXPERIENCE - RETROSPECTIVE DATA ANALYSIS OF THE IBD COHORT ORDENSKLINIKUM LINZ
USTEKINUMAB FOR ULCERATIVE COLITIS A REAL-WORLD EXPERIENCE - RETROSPECTIVE DATA ANALYSIS OF THE IBD COHORT ORDENSKLINIKUM LINZ

ADHERENCE TO VACCINATION RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE PATIENT: A LONG WAY FOR IMPROVING.
ADHERENCE TO VACCINATION RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE PATIENT: A LONG WAY FOR IMPROVING.

SARS-COV-2 VACCINE ACCEPTANCE AMONG GASTROENTEROLOGIST AND INFLAMMATORY BOWEL DISEASE PATIENTS: VACUNEII PROJECT
SARS-COV-2 VACCINE ACCEPTANCE AMONG GASTROENTEROLOGIST AND INFLAMMATORY BOWEL DISEASE PATIENTS: VACUNEII PROJECT

VACCINATION STRATEGIES IN INFLAMMATORY BOWEL DISEASE PATIENTS: PERSPECTIVE OF PHYSICIANS AND PATIENTS.
VACCINATION STRATEGIES IN INFLAMMATORY BOWEL DISEASE PATIENTS: PERSPECTIVE OF PHYSICIANS AND PATIENTS.

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI
IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY

QINGCHANG WENZHONG DECOCTION ACCELERATES INTESTINAL MUCOSAL HEALING THROUGH MODULATION OF DYSREGULATED GUT MICROBIOTA IN DSS-INDUCED COLITIS MICE
QINGCHANG WENZHONG DECOCTION ACCELERATES INTESTINAL MUCOSAL HEALING THROUGH MODULATION OF DYSREGULATED GUT MICROBIOTA IN DSS-INDUCED COLITIS MICE

MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS
MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS

EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS
EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS

TELEDERMA: TELEMEDICINE SYSTEM FOR DERMATOLOGICAL LESIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
TELEDERMA: TELEMEDICINE SYSTEM FOR DERMATOLOGICAL LESIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

EVALUATION OF A COMPUTATIONAL PLATFORM FOR PREDICTING TEMPORAL PROGRESSION OF MUCOSAL DAMAGE AND HEALING IN PATIENTS WITH CROHN'S DISEASE
EVALUATION OF A COMPUTATIONAL PLATFORM FOR PREDICTING TEMPORAL PROGRESSION OF MUCOSAL DAMAGE AND HEALING IN PATIENTS WITH CROHN'S DISEASE

COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITH LOWER DISABILITY THAN PARTIAL MUCOSAL HEALING IN CROHN'S DISEASE: A PROSPECTIVE MULTICENTRIC STUDY.
COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITH LOWER DISABILITY THAN PARTIAL MUCOSAL HEALING IN CROHN'S DISEASE: A PROSPECTIVE MULTICENTRIC STUDY.

FEAR OF COVID-19 AMONG PERSONS WITH IBD ACCORDING TO EMPLOYMENT STATUS, EDUCATIONAL BACKGROUND AND RESIDENTIAL SETTING, AS COMPARED TO PERSONS WITH OTHER GASTROINTESTINAL CONDITIONS
FEAR OF COVID-19 AMONG PERSONS WITH IBD ACCORDING TO EMPLOYMENT STATUS, EDUCATIONAL BACKGROUND AND RESIDENTIAL SETTING, AS COMPARED TO PERSONS WITH OTHER GASTROINTESTINAL CONDITIONS

ARTIFICIAL INTELLIGENCE SURPASSES GASTROINTESTINAL EXPERTS IN THE CLASSIFICATION OF ENDOSCOPIC SEVERITY AMONG ULCERATIVE COLITIS
ARTIFICIAL INTELLIGENCE SURPASSES GASTROINTESTINAL EXPERTS IN THE CLASSIFICATION OF ENDOSCOPIC SEVERITY AMONG ULCERATIVE COLITIS

EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE
EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

PECULIARITIES OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM DEPENDING ON ACTIVITY RATE OF CROHN'S DISEASE
PECULIARITIES OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM DEPENDING ON ACTIVITY RATE OF CROHN'S DISEASE

Item 261 - 280 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13
14
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29